论文部分内容阅读
目的探讨血管紧张素受体拮抗剂厄贝沙坦治疗肾移植术后红细胞增多症的疗效和安全性。方法肾移植术后红细胞增多症患者46例接受厄贝沙坦治疗6月(150mg/d),观察服药前后红细胞压积、血红蛋白、红细胞计数、白细胞计数、血小板计数变化情况。结果服用药物后2月,过高红细胞压积明显下降(P<0.05),其中部分患者用药2周后红细胞压积下降至正常水平,且可以稳定在正常范围。厄贝沙坦对患者血白细胞和血小板计数无明显影响。结论厄贝沙坦治疗肾移植术后红细胞增多症安全、有效。
Objective To investigate the efficacy and safety of angiotensin Ⅱ receptor antagonist irbesartan in the treatment of polycythemia after renal transplantation. Methods 46 patients with polycythemia after renal transplantation received irbesartan for 6 months (150mg / d). The changes of hematocrit, hemoglobin, red blood cell count, white blood cell count and platelet count were observed before and after treatment. Results After 2 months of treatment, the over-height hematocrit decreased significantly (P <0.05). Some of the patients dropped to the normal level after 2 weeks of treatment and were stable in the normal range. Irbesartan on the patient’s white blood cell and platelet count had no significant effect. Conclusion Irbesartan in the treatment of polycythemia after renal transplantation is safe and effective.